4.5 Article

Duration of untreated bipolar disorder: missed opportunities on the long road to optimal treatment

Journal

ACTA PSYCHIATRICA SCANDINAVICA
Volume 127, Issue 2, Pages 136-144

Publisher

WILEY-BLACKWELL
DOI: 10.1111/j.1600-0447.2012.01917.x

Keywords

bipolar disorder; duration of untreated illness; onset; course; suicide

Categories

Funding

  1. INSERM, Paris, France
  2. Assistance Publique-Hopitaux de Paris, Paris, France
  3. RTRS Sante Mentale (Fondation FondaMental), Creteil, France
  4. Agence Nationale pour la Recherche (ANR), Paris, France
  5. Fondation pour la Recherche sur le Cerveau (FRC), Paris, France
  6. National Alliance for Research on Schizophrenia and Depression (NARSAD), Great Neck, New York
  7. Sanofi-Aventis
  8. Lundbeck
  9. AstraZeneca
  10. Eli Lilly
  11. Bristol-Myers Squibb
  12. Servier
  13. BMS-Otsuka
  14. GSK
  15. Jansen-Cilag

Ask authors/readers for more resources

Objective: Duration of untreated illness represents a potentially modifiable component of any diagnosis-treatment pathway. In bipolar disorder (BD), this concept has rarely been systematically defined or not been applied to large clinically representative samples. Method: In a well-characterized sample of 501 patients with BD, we estimated the duration of untreated bipolar disorder (DUB: the interval between the first major mood episode and first treatment with a mood stabilizer). Associations between DUB and clinical onset and the temporal sequence of key clinical milestones were examined. Results: The mean DUB was 9.6 years (SD 9.7; median 6). The median DUB for those with a hypomanic onset (14.5 years) exceeded that for depressive (13 years) and manic onset (8 years). Early onset BD cases have the longest DUB (P < 0.0001). An extended DUB was associated with more mood episodes (P < 0.0001), more suicidal behaviour (P = 0.0003) and a trend towards greater lifetime mood instability (e.g. rapid cycling, possible antidepressant-induced mania). Conclusion: Duration of untreated bipolar disorder (DUB) will only be significantly reduced by more aggressive case finding strategies. Reliable diagnosis (especially for BD-II) and/or instigation of recommended treatments is currently delayed by insufficient awareness of the early, polymorphous presentations of BD, lack of systematic screening and/or failure to follow established guidelines.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available